×
About 128 results

ALLMedicine™ Breast Cancer Guidelines Center

Research & Reviews  28 results

How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technica...
https://doi.org/10.1245/s10434-021-10986-z 10.1245/s10434-014-4282-5 10.1002/jso.20670 10.1007/s00066-014-0687-0 10.1016/j.ejso.2020.10.014 10.3332/ecancer.2016.674 10.1007/s10549-019-05402-w 10.1200/jco.2017.76.5719 10.1016/j.jamcollsurg.2006.06.015 10.1155/2018/4736263 10.1007/s10549-015-3571-4 10.1016/j.jamcollsurg.2008.06.139 10.1245/s10434-018-6358-0 10.1245/s10434-015-4971-8 10.1245/s10434-019-07272-4 10.1245/s10434-019-07629-9 10.1007/s00259-010-1640-9 10.1155/2019/8404035 10.1007/s10549-007-9880-5 10.1016/s0959-8049(99)00133-1 10.1016/j.ejso.2015.05.015 10.1177/000313481908501235 10.1016/j.amjsurg.2009.06.007 10.1245/s10434-009-0841-6 10.1016/j.breast.2012.06.013 10.1016/j.radonc.2018.08.001 10.21037/gs.2017.07.17 10.1152/ajpcell.00535.2009 10.1245/s10434-014-4338-6 10.1245/s10434-018-6384-y 10.1016/s0959-8049(98)00301-3 10.1097/sla.0000000000002310 10.1200/jco.2000.18.8.1696 10.1056/NEJMoa1804710 10.1056/NEJMoa1602253 10.1200/jco.2017.74.6586 10.1245/aso.2003.01.004 10.1016/j.breast.2007.11.004 10.1245/s10434-012-2625-7 10.1007/s00066-015-0939-7 10.1007/s00066-013-0543-7 10.1200/jco.2000.18.15.2817 10.1007/s10549-005-9033-7 10.21037/gs-20-405 10.1016/j.clbc.2017.03.008 10.1016/j.ijrobp.2007.06.035
Annals of Surgical Oncology; Vicini E, Leonardi MC et. al.

Nov 10th, 2021 - The latest National Comprehensive Cancer Network Breast Cancer Guidelines still discourage repeat sentinel node biopsy (SNB) after mastectomy, and the largest multicentric study available reports only 35 cases in the absence of previous axillary d...

Receipt of guideline-concordant care among young adult women with breast cancer.
https://doi.org/10.1002/cncr.33652
Cancer White DP, Kurian AW et. al.

Jun 2nd, 2021 - Little is known about the real-world care of young adult (YA) females (aged 20-39 years) with breast cancer. This study describes factors associated with the receipt of guideline-concordant care (GCC) among YAs. The authors identified 1259 YA wome...

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an A...
https://doi.org/10.12659/AJCR.928012
The American Journal of Case Reports; Osmani AH, Tulbah AM et. al.

Feb 6th, 2021 - BACKGROUND Invasive lobular carcinoma is special subtype of breast cancer that has clinical behavior and morphology distinct from other breast cancer subtypes. It accounts for 5-15% of breast cancer. Overall, HER-2 gene amplification occurs at a s...

Adherence to breast cancer guidelines is associated with better survival outcomes: a sy...
https://doi.org/10.1186/s12913-020-05753-x
BMC Health Services Research; Ricci-Cabello I, Vásquez-Mejía A et. al.

Oct 9th, 2020 - Breast cancer (BC) clinical guidelines offer evidence-based recommendations to improve quality of healthcare for patients with or at risk of BC. Suboptimal adherence to recommendations has the potential to negatively affect population health. Howe...

Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592930
Public Health Genomics; Augustinsson A, Ellberg C et. al.

Jul 9th, 2020 - Swedish national breast cancer guidelines recommend that all women diagnosed with breast cancer (BC) at the age of 35 years or younger should be referred to their regional oncogenetic clinic for genetic counseling and testing, regardless of family...

see more →

News  23 results

Prostate Cancer Guidelines Lack Molecular Test Recommendations
https://www.onclive.com/view/prostate-cancer-guidelines-lack-molecular-test-recommendations

Oct 6th, 2021 - Daniel Lin, MD When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platf...

BrighTNess Follow-Up Data Shed Light on TNBC Therapy
https://www.medscape.com/viewarticle/959033

Sep 18th, 2021 - Details of what works, and what doesn't, in triple-negative breast cancer (TNBC) come from long-term follow-up of the phase 3 randomized BrighTNess trial. The initial improvement that was seen in pathologic complete response (pCR) rates with the a...

AI-Digital Breast Cancer Risk Assessment Platform Accurately Classifies Low-Risk Recurrence Scores
https://www.onclive.com/view/ai-digital-breast-cancer-risk-assessment-platform-accurately-classifies-low-risk-recurrence-scores

Aug 19th, 2021 - The artificial intelligence (AI)–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain (H&E) images and limi...

Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data
https://www.medscape.com/viewarticle/953484

Jun 21st, 2021 - The American Society of Clinical Oncology (ASCO) now recommends offering 1 year of adjuvant olaparib therapy to patients with early-stage HER2-negative, BRCA-mutated breast cancer who have completed chemotherapy and local treatment. The change in ...

NCCN Guidelines Gain Traction Around the Globe
https://www.onclive.com/view/nccn-guidelines-gain-traction-around-the-globe

Dec 5th, 2020 - Robert W. Carlson, MD, CEO of NCCN Figure 1. Downloads of NCCN Guidelines up More Than 600% Since 2006 Global use of cancer management guidelines from the National Comprehensive Cancer Network (NCCN) has climbed rapidly in recent years. A rele...

see more →